Floatz logo

Bortezomib

1Q21 Amplification

Institute of Hematology & Blood Diseases Hospital, ChinaSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the 1Q21 Amplification cohort.

Asset / SponsorPhaseRating
Evomela
Institute of Hematology & Blood Diseases Hospital, China
N/AD
Fludarabine
Institute of Hematology & Blood Diseases Hospital, China
N/AD
DEXAMETHASONE
Institute of Hematology & Blood Diseases Hospital, China
N/AD

Same molecule, other indications

Bortezomib is also rated in:

non-small cell lung carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
BB
Indicative ·
71 / 100
View asset →
follicular lymphomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →